DIA India New Paradigms in Translational Research and Early Phase Development Combining Science with Real World Considerations



12th July, 2019 | Mumbai, India

Supported by

Association of Contract Research Organizations (ACRO)



PROGRAMME COMMITTEE



Manjunath Ramarao Head Discovery and Translational Medicine Bristol-Myers Squibb, BBRC



Sonica Batra Senior Director and Head Medical Sciences Dr. Reddy's Laboratories



Kiran MarthakGlobal Head -Clinical Development
Lambda Therapeutic Research



Ammar Raza Sub Region Medical Director India, Middle East & Africa (IMEA) Allergan



Charu Gautam Senior Medical Director and Head Phase I IQVIA



Jagannath Kota Associate Director- PK Sciences Novartis

In today's world, where regulators, payers and the global biopharmaceutical industry is working relentlessly towards smarter and smaller trials, pre-clinical, clinical and real-world considerations must combine for formulating compelling early development strategies. With the advent of translational research, leveraging promising laboratory and pre-clinical findings to design an effective Phase I approach including first in humans, proof-of-concept and other preliminary efficacy studies, will yield outcomes for promising drug candidates to reach the market faster and more effectively.

Objective

With this program, DIA India aims to provide a dynamic and comprehensive overview of the journey from bench to bedside, drug design with DMPK, artificial intelligence in preclinical development, implementing effective Phase I strategies, starting stronger at proof of concept and leveraging Phase IIa data to plan for a smarter and faster Phase III trial.

Take a look at our key topics for the event and expected participation:

Key Focus Areas

- Reformation Of Early Clinical Development In India- What Lies Ahead?
- Trends in Translational Research to Improve Human Health Outcomes
- · New Frontiers in Early Development- Bioinformatics and Artificial Intelligence
- Central Role of DMPK in Drug Design and Development
- Role of Genomic and Biomarkers in Drug Discovery and Development
- From Bench to Beside- Assessing Preclinical Data for Innovative Early Phase Strategies
- Overcoming Complexities in Oncology Phase I Trials

Key Functions and Departments Participating

- Discovery teams including discovery biology and preclinical teams
- Translational research experts
- Scientific affairs
- Clinical development professionals
- Medical affairs
- · General management
- Regulatory affairs

Keynote Speakers



Neelima Kshirsagar National Chair Clinical Pharmacology ICMR



Murali Ramachandra CEO Aurigene Discovery Technologies Ltd.

Support and Exhibit Opportunities Open!

FOR FURTHER INFORMATION, PLEASE REACH OUT TO: Pradeep Dass

Sr. Manager - Marketing & Business Development

- DIA (India) Private Limited
- cell: +91 91.6053.5566 | Pradeep.dass@diaglobal.org

DIA India Pvt. Ltd.

AGENDA

0,00 0,00	Degistration							
8:00 - 9:00	Registration							
9:00 - 9:30	Opening Ceremony							
9:30 - 10:15	Keynote Presentation 1 REFORMATION OF EARLY CLINICAL DEVELOPMENT IN INDIA- WHAT LIES AHEAD?							
	Neelima Kshirsagar National Chair Clinical Pharmacology, ICMR							
10:15 - 11:00	PANEL DISCUSSION INNOVATIVE EARLY DEVELOPMENT PATHWAYS FOR SUCCESSFUL DRUG DEVELOPMENT - SCIENTIFIC, REGULATORY AND CLINICAL PERSPECTIVES Session Moderator Mubarak Naqvi Head, Insulins Portfolio (China & Emerging Markets); Global Medical Affairs, Sanofi India							
	Panelists							
	Qayum Mukaddam Head - Medical Affairs and Clinical Research Techobserver	Malini AV Lead - Exploratory Clinical and Translational Research Biocon- BMS Research Centre (BBRC)	Chetan Tamhankar Vice President and Head Clinical Development Syngene International Ltd.	Mukesh Kumar Head - Clinical Research & Development Cipla Ltd.				
11:00 - 11:30	Tea/Coffee Break							
11:30 - 12:00	Keynote Presentation 2: STARTING STRONGER EARLY WITH TRANSLATIONAL SCIENCES- BRIDGING DRUG DISCOVERY AND DEVELOPMENT							
	Murali Ramachandra CEO, Aurigene Discovery Technologies Ltd.							
	Session # 1 TRANSLAT	IONAL SCIENCES- FROM DIS	SCOVERY TO REAL WORLD I	HERAPY				
Session Chairs	j							
MANJUNATH RAMARAO Head, Discovery and Translational Medicine Bristol-Myers Squibb, BBRC		JAGANNATH KOTA Associate Director- PK Science Novartis						
12:00 - 12:30	TRENDS IN TRANSLATIONAL SCIENCES TO IMPROVE HUMAN HEALTH OUTCOMES							
	Debarati Mazumder Lead, In-Vitro Pharmacology and Translational Research, Biocon BMS R&D Center (BBRC), Syngene Intl. Ltd							

TRENDS IN TRANSLATIONAL SCIENCES TO IMPROVE HUMAN HEALTH OUTCOMES				
Debarati Mazumder Lead, In-Vitro Pharmacology and Translational Research, Biocon BMS R&D Center (BBRC), Syngene Intl. Ltd				
NEW FRONTIERS IN TRANSLATIONAL SCIENCES - BIOINFORMATICS AND ARTIFICIAL INTELLIGENCE				
Amit Saxena Head, Strategic Research Initiatives, Healthcare and Life Sciences Strategy, Tata Consultancy Services				
OPEN DISCUSSION SESSION				
Session Moderators Manjunath Ramarao Jagannath Kota				
Networking Lunch				

Session # 2 - FUTURISTIC PRECLINICAL DEVELOPMENT - TRENDS AND OPPORTUNITIES

Session Chairs

KIRAN MARTHAK

Global Head - Clinical Development Lambda Therapeutic Research **CHARU GAUTAM**

Senior Medical Director and Head Phase I IOVIA

14:15 - 14:45 CENTRAL ROLE OF DMPK IN DRUG DESIGN AND DEVELOPMENT

Ramachandra Sangana

Senior Investigator, PK Sciences, Novartis

14:45 – 15:15 ROLE OF GENOMICS AND BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT

Pramod Kabra

Director, Healthcare, India and South Asia, Thermofisher

15:15 - 15:30 **OPEN DISCUSSION**

Session Moderators

Kiran Marthak and Charu Gautam

15:30 - 16:00 Tea / Coffee Break

Session#3 - INNOVATIVE REGULATORY AND CLINICAL STRATEGIES FOR EARLY PHASE DEVELOPMENT

Session Chairs

SONICA BATRA

Senior Director and Head Medical Sciences Dr. Reddy's Laboratories AMMAR RAZA

Sub Region Medical Director India, Middle East & Africa (IMEA) Allergan

16:00 - 16:30 INNOVATIVE EARLY DEVELOPMENT STRATEGIES FOR BETTER OUTCOMES

Jamila Joseph

SVP and Head, Innovative Technologies, Reliance Life Sciences Pvt. Ltd.

16:30 – 17:00 OVERCOMING COMPLEXITITIES IN ONCOLOGY PHASE I TRIALS

Anju Gopan

Medical Director - Oncology, IQVIA

17:00 - 17:45 **GRAND PANEL SESSION**

REGULATORY PATHWAYS FOR SUCCESSFUL EARLY DEVELOPMENT- LOCAL AND GLOBAL PERSPECTIVES

Session Moderator

Ramakrishnan Sundaram

Regulatory Affairs, Abbott Healthcare

Panelists

Shravanti Bhowmik

Vice President and Head Program Management, Sun Pharma

Sivakumar Vaidyanathan

General Manager - Clinical Research Operations, Glenmark Pharmaceuticals

Ranga Chandrasekhar

Deputy Drug Controller, CDSCO

Dr. Anand Eswarairah

Head, Medical & Regulatory Affairs, Syngene International

17:45 CLOSING REMARKS

DIA India New Paradigms in Translational Research and Early Phase Development Event I.D. 19651 | 12th July, 2019 | Mumbai, India

VENUE:

COURTYARD BY MARRIOTT MUMBAI INTERNATIONAL AIRPORT SALES EXECUTIVE: THAIRE HUSSAIN PATNI O +91 22 61369987 M +91 8652269279 THAIREHUSSAIN.PATNI@COURTYARD.COM T.S NO. 215 ANDHERI KURLA ROAD ANDHERI EAST MUMBAI, 400059 INDIA

MEETING MANAGER **Pradeep Dass**

Sr. Manager - Marketing & Business Development DIA (India) Private Limited

cell: +91 91.6053.5566 | Pradeep.dass@diaglobal.org

CANCELLATION POLICY: ON OR BEFORE JUNE 30, 2019

- Cancellations must be in writing and received by June 30, 2019
- Registrants who do not cancel in writing by that date and do not attend the event will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations.
- DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.
- UPON CANCELLATION, the administrative fee that will be withheld from refund amount is 25 % of the delegate fee

FULL MEETING CANCELLATION

· All refunds will be issued in the currency of the original payment

Online registrations: visit our website www.diaglobal.org

REGISTRATION FEES FOR ONE DAYS CONFERENCE (Registration fee includes refreshment breaks and luncheons.)

	Basic Rate (INR)	Service Tax 18 %(INR)	Total INF
Early Bird on or before June 2	5th, 2019 (Subject to Payment Realization)		
Industry	6000	1080	7080 🗆
Academia / Govt.	5000	900	5900 🗆
Standard Rate from June 26th,	, 2019 onwards		
Industry	7000	1260	8260 🗆
Academia / Govt.	6000	1080	7080 🗆

DIA MEMBERSHIP

Join DIA now to qualify to save on future events and to receive all the benefits of membership. Visit www.diahome.org and click on Membership for more details

PRIVACY POLICY

DIA respects the privacy of all of its members and customers. To view our policy click the link below

https://www.diaglobal.org/en/about-us/privacy-policy

You agree that your personal data will be transferred to DIA in the US.

STUDENT REGISTRATIONS

A student is an undergraduate/graduate who can document enrollment in a signature accredited, degree granting, academic program. Please send completed registration form, payment and copy of student identification.

Completed form, along with draft/cheque made payable to DIA (India) Private Limited should be sent to:

Bhavesh Vora

Senior Executive Accounts, Bhavesh.vora@diaglobal.org DIA India Pvt. Ltd.

Office No. 250, Unit 1, Level 2, B Wing, Times Square, Andheri Kurla Road, Andheri East, Mumbai 400059

tel: +91 22.6608 9588 | cell: +91 98.2097.2630

PAYMENT DETAILS

Account Name: DIA (INDIA) PRIVATE LIMITED

Account No: 061010200024611 bank Name: AXIS BANK LIMITED

Branch Name: Dhiraj Baug, Near Hari Niwas Circle, LBS Marg, Thane (W)

- 400602

IFSC Code: UTIB0000061 MICR Code: 400211013 Swift Code: AXISINBB061

PAYMENT INFORMATION

Completed form, along with draft/cheque made payable to

DIA (India) Private Limited should be sent to:

Bhavesh Vora

Senior Executive Accounts

bhavesh.vora@diaglobal.org | cell: +91 98 2097 2630

Please check the applicable category:		☐ Industry	☐ Governme	ent 🗖 Academia	a 🔲 Student		
PLEASE PRINT ALL INFOR	MATION CLEARLY						
_ast Name	First Name		M.I.		Please check one:	☐ Mr. ☐	Ms. 🗖 Prof. 🗖 Dr.
Job Position	Affiliation (Company)			☐ Busine	ss Address	☐ Home Address
Address (Please write your address in the format required for delivery to your country.			your country.)	City	P	Postal Country/	
Address							
Telephone Number	Fax	Number		Mobile Number (R	dequired) Email (Required for	confirmation)